Literature DB >> 28144912

SPRINTT and the involvement of stakeholders: strategy and structure.

Régis Le Lain1, Claire Ignaszewski2, Ingrid Klingmann2,3, Alfredo Cesario2,4, Willem Ivo de Boer2,5.   

Abstract

The current healthcare systems are built around the traditional paradigm of patients suffering from a single acute illness. They are, therefore, largely unprepared to face the increasing demands for health services arising from the expansion of an older population with specific medical needs related to multiple chronic disorders. As a consequence, the medical conditions of a large and growing segment of the older European population are not efficiently managed by the available healthcare services. In the context of an aging population, policy makers such as the European Commission and European Institutions, such as the European Medicines Agency (EMA), devote time and resources to study and accompany the need of the aging population. The EMA recognizes the importance of making sure that the needs of the Elderly are considered during development, approval, and use of new medicines, and, therefore, engages with healthcare professional organisations. The Sarcopenia and Physical Frailty in Older People: Multicomponent Intervention Strategies (SPRINTT) is the obvious result of these strategies. The present article describes the SPRINTT workpackage activities aimed at engaging the scientific discussion on the physical frailty and sarcopenia with the EMA as one of its interlocutor, acknowledging the need to collaborate on this topic to foster a productive dialogue.

Entities:  

Keywords:  EMA; Frailty; Policy makers; Sarcopenia

Mesh:

Year:  2017        PMID: 28144912     DOI: 10.1007/s40520-016-0706-3

Source DB:  PubMed          Journal:  Aging Clin Exp Res        ISSN: 1594-0667            Impact factor:   3.636


  1 in total

1.  Bridging the gap between the laboratory and the clinic for patients with sarcopenia.

Authors:  Miles D Witham
Journal:  Biogerontology       Date:  2018-12-27       Impact factor: 4.277

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.